Cancers are characterized by genomic instability and the resulting intra-clonal diversity is a prerequisite for tumor evolution. Therefore, metrics of tumor heterogeneity may prove to be clinically meaningful. Intra-clonal heterogeneity in follicular lymphoma (FL) is apparent from studies of somatic hypermutation (SHM) caused by Activation Induced Deaminase (AID) in IGH. Aberrant SHM (aSHM), defined as AID activity outside of the IG loci, predominantly targets non-coding regions causing numerous “passenger” mutations but has the potential to generate rare significant “driver” mutations. The quantitative relationship between SHM and aSHM has not been defined. To measure SHM and aSHM, ultradeep sequencing (>20,000 fold coverage) was performed on IGH (∼1650nt) and 9 other non-coding regions potentially targeted by AID (combined 9411nt), including the 5′UTR of BCL2. Single nucleotide variants (SNV) were found in 12/12 FL specimens (median 136 SHM and 53 aSHM). The aSHM SNVs were associated with AID-motifs (p<0.0001). The number of SNVs at BCL2 varied widely among specimens and correlated with the number of SNVs at 8 other potential aSHM sites. In contrast SHM at IGH was not predictive of aSHM. Tumor heterogeneity is apparent from SNVs at low variant allele frequencies (VAF); the relative number of SNVs with VAF<5% varied with clinical grade indicating that tumor heterogeneity based on aSHM reflects a clinically meaningful parameter. These data suggest that genome-wide aSHM may be estimated from aSHM of BCL2 but not SHM of IGH. The results demonstrate a practical approach to the quantification of intra-tumoral genetic heterogeneity for clinical specimens.